Anchiano Therapeutics Schedules TASE Delisting

Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer

Tel Aviv-listed biotech company Anchiano Therapeutics Ltd., formerly known as BioCanCell Ltd., has announced Thursday it will delist from the Tel Aviv Stock Exchange on June 17, 2019. Delisting will maximize shareholder value, the company said.

 

Founded in 2004 and based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer.

 

Anchiano listed on Nasdaq in February, as part of a $22.8 million investment deal announced in 2017.

 

The Tel Aviv Stock Exchange. Photo: Orel Cohen